Boston Scientific Corporation
BSX
$101.08
$2.162.18%
NYSE
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 8.36% | 2.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.36% | 2.16% | |||
| Cost of Revenue | 12.00% | 2.97% | |||
| Gross Profit | 6.71% | 1.80% | |||
| SG&A Expenses | 3.20% | 8.02% | |||
| Depreciation & Amortization | 9.76% | -3.76% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.02% | 5.12% | |||
| Operating Income | 10.03% | -10.14% | |||
| Income Before Tax | -12.56% | 59.29% | |||
| Income Tax Expenses | -88.50% | 104.08% | |||
| Earnings from Continuing Operations | 19.83% | 45.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.68% | 44.75% | |||
| EBIT | 10.03% | -10.14% | |||
| EBITDA | 11.13% | -7.75% | |||
| EPS Basic | 20.35% | 44.58% | |||
| Normalized Basic EPS | 17.25% | -11.07% | |||
| EPS Diluted | 19.22% | 44.77% | |||
| Normalized Diluted EPS | 17.13% | -11.14% | |||
| Average Basic Shares Outstanding | 0.10% | 0.14% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||